HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TYKERB safely and effectively. See full prescribing information for TYKERB.

TYKERB (lapatinib) tablets

Initial U.S. Approval: 2007

WARNING: HEPATOTOXICITY

See full prescribing information for complete boxed warning. Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. [See Warnings and Precautions (5.2).]

------RECENT MAJOR CHANGES ----

Boxed Warning.		Month YEAR
Hepatotoxicity. (5.2, 1	7.6)	Month YEAR
Interstitial lung disease	e and pneumonitis. (5.5)	August 2007

----INDICATIONS AND USAGE ---

TYKERB®, a kinase inhibitor, is indicated in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. (1)

----- DOSAGE AND ADMINISTRATION ----

The recommended dosage of TYKERB is 1,250 mg (5 tablets) given orally once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m²/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. (2.1)

- TYKERB should be taken at least one hour before or one hour after a meal. However, capecitabine should be taken with food or within 30 minutes after food. (2.1)
- TYKERB should be taken once daily. Do not divide daily doses of TYKERB. (2.1, 12.3)
- Modify dose for cardiac and other toxicities, severe hepatic impairment, and CYP3A4 drug interactions. (2.2)
- ------ DOSAGE FORMS AND STRENGTHS ------250 mg tablets (3)

-----CONTRAINDICATIONS ------

None. (4)

3

FULL PRESCRIBING INFORMATION: CONTENTS*

INDICATIONS AND USAGE 1

- DOSAGE AND ADMINISTRATION 2
- **Recommended Dosing** 2.1
- Dose Modification Guidelines 22
- DOSAGE FORMS AND STRENGTHS
- CONTRAINDICATIONS 4
- 5 WARNINGS AND PRECAUTIONS
 - Decreased Left Ventricular Election Fraction 5.1
 - 5.2 Hepatotoxicity
 - 5.3 Patients with Severe Hepatic Impairment
 - 5.4 Diarrhea
 - 5.5 Interstitial Lung Disease/Pneumonitis
 - 5.6 QT Prolongation

5.7 Pregnancy ADVERSE REACTIONS 6

Clinical Trials Experience 61

DRUG INTERACTIONS 7

- Effects of Lapatinib on Drug Metabolizing 7.1
- Enzymes and Drug Transport Systems
- 7.2 Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes
- 7.3 Drugs that Inhibit Drug Transport Systems
- Other Chemotherapy Agents 7.4

--- WARNINGS AND PRECAUTIONS -----

- Decreases in left ventricular ejection fraction have been reported. Confirm normal LVEF before starting TYKERB and continue evaluations during treatment. (5.1)
- Lapatinib has been associated with hepatotoxicity. Monitor liver function tests before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. Discontinue and do not restart TYKERB if patients experience severe changes in liver function tests. (5.2)
- Dose reduction in patients with severe hepatic impairment should be considered. (2.2, 5.3, 8.7)
- Diarrhea, including severe diarrhea, has been reported during treatment. Manage with anti-diarrheal agents, and replace fluids and electrolytes if severe. (5.4)
- Lapatinib has been associated with interstitial lung disease and pneumonitis. Discontinue TYKERB if patients experience severe pulmonary symptoms. (5.5)
- Lapatinib prolongs the QT interval in some patients. Consider ECG and electrolyte monitoring. (5.6)
- Fetal harm can occur when administered to a pregnant woman. Women should be advised not to become pregnant when taking TYKERB. (5.7) - ADVERSE REACTIONS --

The most common (>20%) adverse reactions during treatment with TYKERB plus capecitabine were diarrhea, palmar-plantar erythrodysesthesia, nausea, rash, vomiting, and fatigue. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----DRUG INTERACTIONS ------

- TYKERB is likely to increase exposure to concomitantly administered drugs which are metabolized by CYP3A4 or CYP2C8. (7.1)
- Avoid strong CYP3A4 inhibitors. If unavoidable, consider dose reduction of TYKERB in patients coadministered a strong CYP3A4 inhibitor. (2.2, 7.2)
- Avoid strong CYP3A4 inducers. If unavoidable, consider gradual dose increase of TYKERB in patients coadministered a strong CYP3A4 inducer. (2.2, 7.2)

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling.

Revised: Month YEAR ТКВ:ХРІ

USE IN SPECIFIC POPULATIONS 8

- Pregnancy 8.1
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- Geriatric Use 8.5
- **Renal Impairment** 8.6
- Hepatic Impairment 87
- 10 **OVERDOSAGE**
- DESCRIPTION 11
- 12 **CLINICAL PHARMACOLOGY**
 - Mechanism of Action 12.1
 - 12.3 Pharmacokinetics
 - QT Prolongation 12.4
- NONCLINICAL TOXICOLOGY 13
- Carcinogenesis, Mutagenesis, Impairment of Fertility 13.1 CLINICAL STUDIES 14
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- PATIENT COUNSELING INFORMATION 17
 - 17.1 **Decreased Left Ventricular Ejection Fraction**
 - 17.2 Diarrhea
 - 17.3 **Drug Interactions**
 - 17.4 Food
 - 17.5 **Divided Dosina**
 - FDA-Approved Patient Labeling 17.6

*Sections or subsections omitted from the full prescribing information are not listed.

1 FULL PRESCRIBING INFORMATION

2 3

4

5

WARNING: HEPATOTOXICITY

Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. [See Warnings and Precautions (5.2).]

6 1 INDICATIONS AND USAGE

7 TYKERB is indicated in combination with capecitabine for the treatment of patients with 8 advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received

9 prior therapy including an anthracycline, a taxane, and trastuzumab.

10 2 DOSAGE AND ADMINISTRATION

11 2.1 Recommended Dosing

12 The recommended dose of TYKERB is 1,250 mg (5 tablets) given orally once daily on 13 Days 1-21 continuously in combination with capecitabine 2,000 mg/m²/day (administered orally 14 in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. TYKERB

15 should be taken at least one hour before or one hour after a meal. The dose of TYKERB should

16 be once daily; dividing the daily dose is not recommended [see Clinical Pharmacology (12.3)].

17 Capecitabine should be taken with food or within 30 minutes after food. If a day's dose is

18 missed, the patient should not double the dose the next day. Treatment should be continued until

19 disease progression or unacceptable toxicity occurs.

20 **2.2 Dose Modification Guidelines**

<u>Cardiac Events:</u> TYKERB should be discontinued in patients with a decreased left
 ventricular ejection fraction (LVEF) that is Grade 2 or greater by NCI Common Terminology
 Criteria for Adverse Events (NCI CTCAE) and in patients with an LVEF that drops below the
 institution's lower limit of normal *[see Warnings and Precautions (5.1) and Adverse Reactions* (6.1)]. TYKERB may be restarted at a reduced dose (1,000 mg/day) after a minimum of 2 weeks

26 if the LVEF recovers to normal and the patient is asymptomatic.

27 <u>Hepatic Impairment:</u> Patients with severe hepatic impairment (Child-Pugh Class C)

28 should have their dose of TYKERB reduced. A dose reduction to 750 mg/day in patients with

29 severe hepatic impairment is predicted to adjust the area under the curve (AUC) to the normal

30 range and should be considered. However, there is no clinical data with this dose adjustment in

31 patients with severe hepatic impairment.

32 Concomitant Strong CYP3A4 Inhibitors: The concomitant use of strong CYP3A4

33 inhibitors should be avoided (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,

34 indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole). Grapefruit

35 may also increase plasma concentrations of lapatinib and should be avoided. If patients must be

- 36 coadministered a strong CYP3A4 inhibitor, based on pharmacokinetic studies, a dose reduction
- 37 to 500 mg/day of lapatinib is predicted to adjust the lapatinib AUC to the range observed without
- 38 inhibitors and should be considered. However, there are no clinical data with this dose
- 39 adjustment in patients receiving strong CYP3A4 inhibitors. If the strong inhibitor is
- 40 discontinued, a washout period of approximately 1 week should be allowed before the lapatinib
- 41 dose is adjusted upward to the indicated dose. [See Drug Interactions (7.2).]
- 42 Concomitant Strong CYP3A4 Inducers: The concomitant use of strong CYP3A4
- 43 inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin,
- 44 rifapentin, phenobarbital, St. John's Wort). If patients must be coadministered a strong CYP3A4
- 45 inducer, based on pharmacokinetic studies, the dose of lapatinib should be titrated gradually
- 46 from 1,250 mg/day up to 4,500 mg/day based on tolerability. This dose of lapatinib is predicted
- 47 to adjust the lapatinib AUC to the range observed without inducers and should be considered.
- 48 However, there are no clinical data with this dose adjustment in patients receiving strong
- 49 CYP3A4 inducers. If the strong inducer is discontinued the lapatinib dose should be reduced to
- 50 the indicated dose. [See Drug Interactions (7.2).]
- 51 Other Toxicities: Discontinuation or interruption of dosing with TYKERB may be
- 52 considered when patients develop \geq Grade 2 NCI CTC toxicity and can be restarted at
- 53 1,250 mg/day when the toxicity improves to Grade 1 or less. If the toxicity recurs, then
- 54 TYKERB should be restarted at a lower dose (1,000 mg/day).
- See manufacturer's prescribing information for capecitabine dosage adjustment
 guidelines in the event of toxicity.
- 57 3 DOSAGE FORMS AND STRENGTHS
- 58 250 mg tablets oval, biconvex, orange, film-coated with GS XJG debossed on one
 59 side.
- 60 4 CONTRAINDICATIONS
- 61 None.
- 62 See manufacturer's prescribing information for capecitabine contraindications.
- 63 5 WARNINGS AND PRECAUTIONS

64 5.1 Decreased Left Ventricular Ejection Fraction

TYKERB has been reported to decrease LVEF [see Adverse Reactions (6.1)]. In the
randomized clinical trial, the majority (>60%) of LVEF decreases occurred within the first
weeks of treatment; however, data on long-term exposure are limited. Caution should be taken

- 68 if TYKERB is to be administered to patients with conditions that could impair left ventricular
- 69 function. LVEF should be evaluated in all patients prior to initiation of treatment with TYKERB
- 70 to ensure that the patient has a baseline LVEF that is within the institution's normal limits. LVEF
- should continue to be evaluated during treatment with TYKERB to ensure that LVEF does not
- decline below the institution's normal limits [see Dosage and Administration (2.2)].

73 5.2 **Hepatotoxicity**

74 Hepatotoxicity (ALT or AST >3 times the upper limit of normal and total bilirubin 75 >1.5 times the upper limit of normal) has been observed in clinical trials (<1% of patients) and 76 postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. 77 Causality of the deaths is uncertain. The hepatotoxicity may occur days to several months after 78 initiation of treatment. Liver function tests (transaminases, bilirubin, and alkaline phosphatase) 79 should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as 80 clinically indicated. If changes in liver function are severe, therapy with TYKERB should be 81 discontinued and patients should not be retreated with TYKERB [see Adverse Reactions (6.1)].

82 5.3 Patients with Severe Hepatic Impairment

If TYKERB is to be administered to patients with severe pre-existing hepatic impairment,

83 84 dose reduction should be considered [see Dosage and Administration (2.2) and Use in Specific 85 *Populations* (8.7). In patients who develop severe hepatotoxicity while on therapy, TYKERB 86 should be discontinued and patients should not be retreated with TYKERB [see Warnings and 87 Precautions (5.2)].

88 5.4 Diarrhea

89 Diarrhea, including severe diarrhea, has been reported during treatment with TYKERB 90 [see Adverse Reactions (6.1)]. Proactive management of diarrhea with anti-diarrheal agents is 91 important. Severe cases of diarrhea may require administration of oral or intravenous electrolytes 92 and fluids, and interruption or discontinuation of therapy with TYKERB.

93

5.5 Interstitial Lung Disease/Pneumonitis

94 Lapatinib has been associated with interstitial lung disease and pneumonitis in 95 monotherapy or in combination with other chemotherapies [see Adverse Reactions (6.1)]. 96 Patients should be monitored for pulmonary symptoms indicative of interstitial lung disease or 97 pneumonitis. TYKERB should be discontinued in patients who experience pulmonary symptoms 98 indicative of interstitial lung disease/pneumonitis which are \geq Grade 3 (NCI CTCAE).

99 5.6 **QT** Prolongation

100 QT prolongation measured by automated machine-read evaluation of ECG was observed 101 in an uncontrolled, open-label dose escalation study of lapatinib in advanced cancer patients [see 102 *Clinical Pharmacology* (12.4)]. Lapatinib should be administered with caution to patients who 103 have or may develop prolongation of QTc. These conditions include patients with hypokalemia 104 or hypomagnesemia, with congenital long QT syndrome, patients taking anti-arrhythmic 105 medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose 106 anthracycline therapy. Hypokalemia or hypomagnesemia should be corrected prior to lapatinib 107 administration. The prescriber should consider baseline and on-treatment electrocardiograms 108 with QT measurement.

109 5.7 Pregnancy

110 Pregnancy Category D

TYKERB can cause fetal harm when administered to a pregnant woman. In a study 111 112 where pregnant rats were dosed with lapatinib during organogenesis and through lactation, at a

- 113 dose of 120 mg/kg/day (approximately 6.4 times the human clinical exposure based on AUC),
- 114 91% of the pups had died by the fourth day after birth, while 34% of the 60 mg/kg/day pups were
- dead. The highest no-effect dose for this study was 20 mg/kg/day (approximately equal to the
- 116 human clinical exposure based on AUC).
- 117 Lapatinib was studied for effects on embryo-fetal development in pregnant rats and
- rabbits given oral doses of 30, 60, and 120 mg/kg/day. There were no teratogenic effects;
- 119 however, minor anomalies (left-sided umbilical artery, cervical rib, and precocious ossification)
- 120 occurred in rats at the maternally toxic dose of 120 mg/kg/day (approximately 6.4 times the
- 121 human clinical exposure based on AUC). In rabbits, lapatinib was associated with maternal
- 122 toxicity at 60 and 120 mg/kg/day (approximately 0.07 and 0.2 times the human clinical exposure,
- respectively, based on AUC) and abortions at 120 mg/kg/day. Maternal toxicity was associated
 with decreased fetal body weights and minor skeletal variations.
- 125 There are no adequate and well-controlled studies with TYKERB in pregnant women. 126 Women should be advised not to become pregnant when taking TYKERB. If this drug is used 127 during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be 128 apprised of the potential hazard to the fetus.

129 6 **ADVERSE REACTIONS**

130 6.1 Clinical Trials Experience

The safety of TYKERB has been evaluated in more than 3,500 patients in clinical trials. The efficacy and safety of TYKERB in combination with capecitabine in breast cancer was evaluated in 198 patients in a randomized, Phase 3 trial. *[See Clinical Studies (14).]* Adverse reactions which occurred in at least 10% of patients in either treatment arm and were higher in the combination arm are shown in Table 1.

- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- 139 The most common adverse reactions (>20%) during therapy with TYKERB plus
- 140 capecitabine were gastrointestinal (diarrhea, nausea, and vomiting), dermatologic (palmar-
- 141 plantar erythrodysesthesia and rash), and fatigue. Diarrhea was the most common adverse
- 142 reaction resulting in discontinuation of study medication.
- 143The most common Grade 3 and 4 adverse reactions (NCI CTC v3) were diarrhea and144palmar-plantar erythrodysesthesia. Selected laboratory abnormalities are shown in Table 2.
- 145

	TYKERB	3 1,250 m	g/day +			
	Capecitabine 2,000 mg/m ² /day (N = 198)		Capecitabine 2,500 mg/m ² /day (N = 191)			
		Grade	Grade		Grade	Grade
Reactions	Grades [*] %	3 %	4 %	Grades [*] %	3 %	4 %
Gastrointestinal disorders	/0	/0	/0	/0	/0	/0
Diarrhea	65	13	1	40	10	0
Nausea	44	2	0	43	2	0
Vomiting	26	2	0	21	2	0
Stomatitis	14	0	0	11	<1	0
Dyspepsia	11	<1	0	3	0	0
Skin and subcutaneous tissue disorders						
Palmar-plantar erythrodysesthesia	53	12	0	51	14	0
$Rash^\dagger$	28	2	0	14	1	0
Dry skin	10	0	0	6	0	0
General disorders and administrative site conditions						
Mucosal inflammation	15	0	0	12	2	0
Musculoskeletal and connective tissue disorders						
Pain in extremity	12	1	0	7	<1	0
Back pain	11	1	0	6	<1	0
Respiratory, thoracic, and mediastinal disorders						
Dyspnea	12	3	0	8	2	0
Psychiatric disorders						
Insomnia	10	<1	0	6	0	0

146 **Table 1. Adverse Reactions Occurring in \geq10% of Patients**

^{*} National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.

[†] Grade 3 dermatitis acneiform was reported in <1% of patients in TYKERB plus capecitabine

149 group.

150

	TYKERB 1,250 mg/day + Capecitabine 2,000 mg/m ² /day		Capecitabine 2,500 mg/m²/day			
	All Grades [*]	Grade 3	Grade 4	All Grades [*]	Grade 3	Grade 4
Parameters	%	%	%	%	%	%
Hematologic						
Hemoglobin	56	<1	0	53	1	0
Platelets	18	<1	0	17	<1	<1
Neutrophils	22	3	<1	31	2	1
Hepatic						
Total Bilirubin	45	4	0	30	3	0
AST	49	2	<1	43	2	0
ALT	37	2	0	33	1	0

151 Table 2. Selected Laboratory Abnormalities

152

^{*} National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.

153

154 <u>Decreases in Left Ventricular Ejection Fraction:</u> Due to potential cardiac toxicity 155 with HER2 (ErbB2) inhibitors, LVEF was monitored in clinical trials at approximately 8-week

156 intervals. LVEF decreases were defined as signs or symptoms of deterioration in left ventricular

157 cardiac function that are \geq Grade 3 (NCI CTCAE), or a \geq 20% decrease in left ventricular cardiac

158 ejection fraction relative to baseline which is below the institution's lower limit of normal.

159 Among 198 patients who received lapatinib/capecitabine combination treatment, 3 experienced

Grade 2 and one had Grade 3 LVEF adverse reactions (NCI CTC 3.0). [See Warnings and
 Precautions (5.1).]

101

162 <u>Hepatotoxicity:</u> Lapatinib has been associated with hepatoxicity [see Boxed Warning
 163 and Warnings and Precautions (5.2)].

164 <u>Interstitial Lung Disease/Pneumonitis:</u> Lapatinib has been associated with interstitial
 165 lung disease and pneumonitis in monotherapy or in combination with other chemotherapies [see
 166 Warnings and Precautions (5.5)].

167 7 DRUG INTERACTIONS

7.1 Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport

169 Systems

170 Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.

171 Caution should be exercised and dose reduction of the concomitant substrate drug should be

172 considered when dosing lapatinib concurrently with medications with narrow therapeutic

173 windows that are substrates of CYP3A4 or CYP2C8. Lapatinib did not significantly inhibit the

174 following enzymes in human liver microsomes: CYP1A2, CYP2C9, CYP2C19, and CYP2D6 or

175 UGT enzymes in vitro, however, the clinical significance is unknown.

Lapatinib inhibits human P-glycoprotein. If TYKERB is administered with drugs that are
substrates of Pgp, increased concentrations of the substrate drug are likely, and caution should be
exercised.

179 7.2 Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes

180 Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration

181 of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly (see

- 182 <u>Ketoconazole</u> and <u>Carbamazepine</u> sections, below). Dose adjustment of lapatinib should be
- 183 considered for patients who must receive concomitant strong inhibitors or concomitant strong
- inducers of CYP3A4 enzymes [see Dosage and Administration (2.2)].
- 185 Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at
- 186 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to 187 approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
- 188 <u>Carbamazepine:</u> In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 189 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to 190 lapatinib was decreased approximately 72%.

191 **7.3 Drugs that Inhibit Drug Transport Systems**

- 192 Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1). If
- 193 TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are
- 194 likely, and caution should be exercised.
- 195 **7.4 Other Chemotherapy Agents**
- In a separate study, concomitant administration of lapatinib with capecitabine did notmeaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).
- 1988USE IN SPECIFIC POPULATIONS
- 199 8.1 Pregnancy
- 200 Pregnancy Category D [see Warnings and Precautions (5.7)].

201 8.3 Nursing Mothers

- It is not known whether lapatinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from TYKERB, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother
- discontinue the drug, taking into account the importance of the drug to the mother.

2068.4Pediatric Use207The safety and e

The safety and effectiveness of TYKERB in pediatric patients have not been established.

2088.5Geriatric Use

- Of the total number of metastatic breast cancer patients in clinical studies of TYKERB in combination with capecitabine (N = 198), 17% were 65 years of age and older, and 1% were 75 years of age and older. No overall differences in safety or effectiveness of the combination of TYKERB and capecitabine were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
- 2158.6Renal Impairment
- Lapatinib pharmacokinetics have not been specifically studied in patients with renal
 impairment or in patients undergoing hemodialysis. There is no experience with TYKERB in

- 218 patients with severe renal impairment. However, renal impairment is unlikely to affect the
- 219 pharmacokinetics of lapatinib given that less than 2% (lapatinib and metabolites) of an

administered dose is eliminated by the kidneys.

221 8.7 Hepatic Impairment


- The pharmacokinetics of lapatinib were examined in subjects with pre-existing moderate (n = 8) or severe (n = 4) hepatic impairment (Child-Pugh Class B/C, respectively) and in 8
- healthy control subjects. Systemic exposure (AUC) to lapatinib after a single oral 100-mg dose
- increased approximately 14% and 63% in subjects with moderate and severe pre-existing hepatic
- 226 impairment, respectively. Administration of TYKERB in patients with severe hepatic
- 227 impairment should be undertaken with caution due to increased exposure to the drug. A dose
- reduction should be considered for patients with severe pre-existing hepatic impairment [see
- 229 *Dosage and Administration (2.2)].* In patients who develop severe hepatotoxicity while on
- therapy, TYKERB should be discontinued and patients should not be retreated with TYKERB
- 231 [see Warnings and Precautions (5.2)].

232 **10 OVERDOSAGE**

- There is no known antidote for overdoses of TYKERB. The maximum oral doses of lapatinib that have been administered in clinical trials are 1,800 mg once daily. More frequent ingestion of TYKERB could result in serum concentrations exceeding those observed in clinical trials and could result in increased toxicity. Therefore, missed doses should not be replaced and dosing should resume with the next scheduled daily dose.
- There has been a report of one patient who took 3,000 mg of TYKERB for 10 days. This patient had Grade 3 diarrhea and vomiting on Day 10. The event resolved following IV hydration and interruption of treatment with TYKERB and letrozole.
- Because lapatinib is not significantly renally excreted and is highly bound to plasma
 proteins, hemodialysis would not be expected to be an effective method to enhance the
 elimination of lapatinib.

244 **11 DESCRIPTION**

- 245 Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase
- 246 inhibitors. It is present as the monohydrate of the ditosylate salt, with chemical name N-(3-
- 247 chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-
- 248 (methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine bis(4-
- 249 methylbenzenesulfonate) monohydrate. It has the molecular formula $C_{29}H_{26}ClFN_4O_4S$
- $(C_7H_8O_3S)_2$ H₂O and a molecular weight of 943.5. Lapatinib ditosylate monohydrate has the
- 251 following chemical structure:



252

Lapatinib is a yellow solid, and its solubility in water is 0.007 mg/mL and in 0.1N HCl is 0.001 mg/mL at 25°C.

Each 250 mg tablet of TYKERB contains 405 mg of lapatinib ditosylate monohydrate, equivalent to 398 mg of lapatinib ditosylate or 250 mg lapatinib free base.

257 The inactive ingredients of TYKERB are: **Tablet Core:** Magnesium stearate,

258 microcrystalline cellulose, povidone, sodium starch glycolate. **Coating:** Orange film-coat:

259 FD&C yellow No. 6/sunset yellow FCF aluminum lake, hypromellose, macrogol/PEG 400,

260 polysorbate 80, titanium dioxide.

261 12 CLINICAL PHARMACOLOGY

262 **12.1 Mechanism of Action**

263 Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase 264 domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal 265 Receptor Type 2 (HER2 [ErbB2]) receptors (estimated K_i^{app} values of 3nM and 13nM, 266 respectively) with a dissociation half-life of \geq 300 minutes. Lapatinib inhibits ErbB-driven tumor 267 cell growth in vitro and in various animal models.

An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines.

271 Lapatinib retained significant activity against breast cancer cell lines selected for long-term

272 growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-

273 resistance between these two agents.

274 **12.3 Pharmacokinetics**

Absorption: Absorption following oral administration of TYKERB is incomplete and
 variable. Serum concentrations appear after a median lag time of 0.25 hours (range 0 to

1.5 hour). Peak plasma concentrations (C_{max}) of lapatinib are achieved approximately 4 hours
after administration. Daily dosing of TYKERB results in achievement of steady state within 6 to

279 7 days, indicating an effective half-life of 24 hours.

At the dose of 1,250 mg daily, steady state geometric mean (95% confidence interval) values of C_{max} were 2.43 mcg/mL (1.57 to 3.77 mcg/mL) and AUC were 36.2 mcg.hr/mL (23.4 to 56 mcg.hr/mL). 283 Divided daily doses of TYKERB resulted in approximately 2-fold higher exposure at 284 steady state (steady state AUC) compared to the same total dose administered once daily.

Systemic exposure to lapatinib is increased when administered with food. Lapatinib AUC values were approximately 3- and 4-fold higher (C_{max} approximately 2.5- and 3-fold higher) when administered with a low fat (5% fat-500 calories) or with a high fat (50% fat-1,000

288 calories) meal, respectively.

<u>Distribution:</u> Lapatinib is highly bound (>99%) to albumin and alpha-1 acid
 glycoprotein. In vitro studies indicate that lapatinib is a substrate for the transporters breast
 cancer resistance protein (BCRP, ABCG2) and P-glycoprotein (Pgp, ABCB1). Lapatinib has also
 been shown in vitro to inhibit these efflux transporters, as well as the hepatic uptake transporter
 OATP 1B1, at clinically relevant concentrations.

294 <u>Metabolism:</u> Lapatinib undergoes extensive metabolism, primarily by CYP3A4 and 295 CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated 296 metabolites, none of which accounts for more than 14% of the dose recovered in the feces or 297 10% of lapatinib concentration in plasma.

298 <u>Elimination:</u> At clinical doses, the terminal phase half-life following a single dose was 299 14.2 hours; accumulation with repeated dosing indicates an effective half-life of 24 hours.

Elimination of lapatinib is predominantly through metabolism by CYP3A4/5 with
 negligible (<2%) renal excretion. Recovery of parent lapatinib in feces accounts for a median of
 27% (range 3 to 67%) of an oral dose.

303 <u>Effects of Age, Gender, or Race:</u> Studies of the effects of age, gender, or race on the 304 pharmacokinetics of lapatinib have not been performed.

305 **12.4 QT Prolongation**

The QT prolongation potential of lapatinib was assessed as part of an uncontrolled, openlabel dose escalation study in advanced cancer patients. Eighty-one patients received daily doses of lapatinib ranging from 175 mg/day to 1,800 mg/day. Serial ECGs were collected on Day 1 and Day 14 to evaluate the effect of lapatinib on QT intervals. Thirteen of the 81 subjects were found to have either QTcF (corrected QT by the Friedericia method) >480 msec or an increase in QTcF >60 msec by automated machine-read evaluation of ECG. Analysis of the data suggested a relationship between lapatinib concentration and the QTc interval.

313 13 NONCLINICAL TOXICOLOGY

314 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

- 315 Two-year carcinogenicity studies with lapatinib are ongoing.
- 316 Lapatinib was not clastogenic or mutagenic in the Chinese hamster ovary chromosome
- 317 aberration assay, microbial mutagenesis (Ames) assay, human lymphocyte chromosome
- 318 aberration assay or the in vivo rat bone marrow chromosome aberration assay at single doses up
- to 2,000 mg/kg. However, an impurity in the drug product (up to 4 ppm or 8 mcg/day) was
- 320 genotoxic when tested alone in both in vitro and in vivo assays.

321 There were no effects on male or female rat mating or fertility at doses up to

322 120 mg/kg/day in females and 180 mg/kg/day in males (approximately 6.4 times and 2.6 times

323 the expected human clinical exposure based on AUC, respectively). The effect of lapatinib on

human fertility is unknown. However, when female rats were given oral doses of lapatinib during

325 breeding and through the first 6 days of gestation, a significant decrease in the number of live

fetuses was seen at 120 mg/kg/day and in the fetal body weights at ≥ 60 mg/kg/day

- 327 (approximately 6.4 times and 3.3 times the expected human clinical exposure based on AUC,
- 328 respectively).

329 14 CLINICAL STUDIES

The efficacy and safety of TYKERB in combination with capecitabine in breast cancer were evaluated in a randomized, Phase 3 trial. Patients eligible for enrollment had HER2 (ErbB2) over-expressing (IHC 3+ or IHC 2+ confirmed by FISH), locally advanced or metastatic breast cancer, progressing after prior treatment that included anthracyclines, taxanes, and trastuzumab.

335 Patients were randomized to receive either TYKERB 1,250 mg once daily (continuously) plus capecitabine 2,000 mg/m²/day on Days 1-14 every 21 days, or to receive capecitabine alone 336 at a dose of 2,500 mg/m²/day on Days 1-14 every 21 days. The endpoint was time to progression 337 338 (TTP). TTP was defined as time from randomization to tumor progression or death related to 339 breast cancer. Based on the results of a pre-specified interim analysis, further enrollment was 340 discontinued. Three hundred and ninety-nine (399) patients were enrolled in this study. The 341 median age was 53 years and 14% were older than 65 years. Ninety-one percent (91%) were 342 Caucasian. Ninety-seven percent (97%) had stage IV breast cancer, 48% were estrogen receptor+ 343 (ER+) or progesterone receptor+ (PR+), and 95% were ErbB2 IHC 3+ or IHC 2+ with FISH 344 confirmation. Approximately 95% of patients had prior treatment with anthracyclines, taxanes, 345 and trastuzumab. 346 Efficacy analyses four months after the interim analysis are presented in Table 3, Figure 347 1, and Figure 2.

348

349 **Table 3. Efficacy Results**

	Independent Assessment [*]		Investigator Assessment	
	TYKERB		TYKERB	
	1,250 mg/day +		1,250 mg/day +	
	Capecitabine	Capecitabine	Capecitabine	Capecitabine
	2,000 mg/m ² /day	2,500 mg/m ² /day	2,000 mg/m ² /day	2,500 mg/m ² /day
	(N = 198)	(N = 201)	(N = 198)	(N = 201)
Number of TTP events	82	102	121	126
Median TTP, weeks	27.1	18.6	23.9	18.3
(25 th , 75 th , Percentile),	(17.4, 49.4)	(9.1, 36.9)	(12.0, 44.0)	(6.9, 35.7)
weeks				
Hazard Ratio	0.57		0.72	
(95% CI)	(0.43, 0.77) $(0.56, 0.92)$		0.92)	
p value	0.00013		0.00762	
Response Rate (%)	23.7	13.9	31.8	17.4
(95% CI)	(18.0, 30.3)	(9.5, 19.5)	(25.4, 38.8)	(12.4, 23.4)

 $350 \quad \text{TTP} = \text{Time to progression.}$


351 * The time from last tumor assessment to the data cut-off date was >100 days in approximately

30% of patients in the independent assessment. The pre-specified assessment interval was 42 or84 days.


354

355 Figure 1. Kaplan-Meier Estimates for Independent Review Panel-evaluated Time to

356 **Progression**



357



359

360	At the time of updated analysis, 30% of patients had died and the data for survival
361	analysis are not mature. Fifty-five patients (28%) in the TYKERB plus capecitabine group and
362	64 subjects (32%) in the capecitabine group had died.

363 16 HOW SUPPLIED/STORAGE AND HANDLING

- The 250 mg tablets of TYKERB are oval, biconvex, orange, and film-coated with
- 365 GS XJG debossed on one side and are available in:
- 366 Bottles of 150 tablets: NDC 0173-0752-00
- 367 Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP
- 368 Controlled Room Temperature].

369 17 PATIENT COUNSELING INFORMATION

370 *See FDA-approved patient labeling (17.6).*

371 17.1 Decreased Left Ventricular Ejection Fraction

- 372
 Patients should be informed that TYKERB has been reported to decrease left ventricular
- ejection fraction which may result in shortness of breath, palpitations, and/or fatigue. Patients
- 374 should inform their physician if they develop these symptoms while taking TYKERB.

375 **17.2 Diarrhea**

- Patients should be informed that TYKERB often causes diarrhea which may be severe in
 some cases. Patients should be told how to manage and/or prevent diarrhea and to inform their
- 378 physician if severe diarrhea occurs during treatment with TYKERB.

379 **17.3 Drug Interactions**

TYKERB may interact with many drugs; therefore, patients should be advised to report
 to their healthcare provider the use of any other prescription or nonprescription medication or

- 382 herbal products.
- 383 **17.4 Food**
- Patients should be informed of the importance of taking TYKERB at least one hour before or one hour after a meal, in contrast to capecitabine which should be taken with food or within 30 minutes after food.

387 17.5 Divided Dosing

The dose of TYKERB should not be divided. Patients should be advised of the importance of taking TYKERB once daily, in contrast to capecitabine which is taken twice daily.

390 **17.6 FDA-Approved Patient Labeling**

- 391 Patient labeling is provided as a tear-off leaflet at the end of this full prescribing392 information.
- 393
- 394 TYKERB is a registered trademark of GlaxoSmithKline.
- 395

gsk GlaxoSmithKline

396

397 GlaxoSmithKline

- 398 Research Triangle Park, NC 27709
- 399
- 400 ©YEAR, GlaxoSmithKline. All rights reserved.

401	PHARMACIST - DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT
402 403	
403 404	PATIENT INFORMATION
405	
406	TYKERB (TIE-curb)
407	(lapatinib) tablets
408	
409	Read this leaflet before you start taking TYKERB [®] and each time you get a refill. There may be
410	new information. This information does not take the place of talking with your doctor about your
411	medical condition or treatment.
412	
413	What is TYKERB?
414	TYKERB is used with the medicine capecitabine for the treatment of patients with advanced or
415	metastatic breast cancer that is HER2 positive, and who have already had certain other breast
416	cancer treatments.
417 418	Before you start taking TYKERB, tell your doctor about all of your medical conditions,
418	including if you:
420	have heart problems.
421	 have liver problems. You may need a lower dose of TYKERB.
422	 are pregnant or may become pregnant. TYKERB may harm an unborn baby. If you become
423	pregnant during treatment with TYKERB, tell your doctor as soon as possible.
424	• are breastfeeding. It is not known if TYKERB passes into your breast milk or if it can harm
425	your baby. If you are a woman who has or will have a baby, talk with your doctor about the
426	best way to feed your baby.
427	
428	Tell your doctor about all the medicines you take, including prescription and nonprescription
429	medicines and herbal and dietary supplements. TYKERB and many other medicines may interact
430	with each other. Your doctor needs to know what medicines you take so he or she can choose the
431	right dose of TYKERB for you.
432	
433	Especially tell your doctor if you take:
434	• antibiotics and anti-fungals (drugs used to treat infections)
435	• HIV (AIDS) treatments
436	• anticonvulsant drugs (drugs used to treat seizures)
437	• calcium channel blockers (drugs used to treat certain heart disorders or high blood pressure)
438	antidepressants drugs used for stornegh places
439	 drugs used for stomach ulcers St. John's Wort or other barbal supplements
440	• St. John's Wort or other herbal supplements

441	
442	Know the medicines you take. Keep a list of your medicines with you to show your doctor. Do
443	not take other medicines during treatment with TYKERB without first checking with your
444	doctor.
445	
446	Because TYKERB is given with another drug called capecitabine, you should also discuss with
447	your doctor or pharmacist any medicines that should be avoided when taking capecitabine.
448	
449	How should I take TYKERB?
450	• Take TYKERB exactly as your doctor has told you. TYKERB and capecitabine are taken in
451	21 day cycles. The usual dose of TYKERB is 1,250 mg (5 tablets) taken by mouth, one time
452	a day on days 1 to 21. Your doctor will tell you the dose of capecitabine you should take
453	and when you should take it.
454	• TYKERB should be taken at least one hour before, or at least one hour after food.
455	 Do not eat or drink grapefruit products while taking TYKERB.
456	 Your doctor may adjust your dose of TYKERB depending on how you tolerate the
457	treatment.
458	• If you forget to take your dose of TYKERB, take it as soon as you remember that day. If
459	you miss a day, do not double your dose the next day. Just skip the missed dose.
460	jin in all jin and in a sub-
-00	
461	What are the possible side effects of TYKERB?
	What are the possible side effects of TYKERB? Serious side effects include:
461	
461 462	Serious side effects include:
461 462 463	 Serious side effects include: heart problems
461 462 463 464	 Serious side effects include: heart problems decreased pumping of blood from the heart
461 462 463 464 465	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat
461 462 463 464 465 466	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or
461 462 463 464 465 466 467	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly.
461 462 463 464 465 466 467 468	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB
461 462 463 464 465 466 467 468 469	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment.
461 462 463 464 465 466 467 468 469 470	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment. lung problems
461 462 463 464 465 466 467 468 469 470 471	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment. lung problems
461 462 463 464 465 466 467 468 469 470 471 472	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment. lung problems severe diarrhea, which may lead to you becoming dehydrated
461 462 463 464 465 466 467 468 469 470 471 472 473	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment. lung problems severe diarrhea, which may lead to you becoming dehydrated Call your doctor right away if you have palpitations, persistent cough, shortness of breath,
461 462 463 464 465 466 467 468 469 470 471 472 473 474	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment. lung problems severe diarrhea, which may lead to you becoming dehydrated Call your doctor right away if you have palpitations, persistent cough, shortness of breath,
461 462 463 464 465 466 467 468 469 470 471 472 473 474 475	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment. lung problems severe diarrhea, which may lead to you becoming dehydrated Call your doctor right away if you have palpitations, persistent cough, shortness of breath, or severe diarrhea.
461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment. lung problems severe diarrhea, which may lead to you becoming dehydrated Call your doctor right away if you have palpitations, persistent cough, shortness of breath, or severe diarrhea. Common side effects of TYKERB in combination with capecitabine include:
461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477	 Serious side effects include: heart problems decreased pumping of blood from the heart abnormal heartbeat liver problems, which may cause itching, yellow eyes or skin, dark urine, or pain or discomfort in the right upper area of the belly. Your doctor should do blood tests to check your liver before you start taking TYKERB and during treatment. lung problems severe diarrhea, which may lead to you becoming dehydrated Call your doctor right away if you have palpitations, persistent cough, shortness of breath, or severe diarrhea. Common side effects of TYKERB in combination with capecitabine include: diarrhea

481	• vomiting
482	• tiredness
483	• mouth sores
484	loss of appetite
485	• indigestion
486	
487	Tell your doctor about any side effect that gets serious or that does not go away.
488	
489	These are not all the side effects with TYKERB. Ask your doctor or pharmacist for more
490	information.
491	
492	You may also get side effects from capecitabine. Talk to your doctor about possible side
493	effects with capecitabine.
494	-
495	How should I store TYKERB tablets?
496	• Store TYKERB tablets at room temperature between 59° and 86°F (15° to 30°C). Keep the
497	container closed tightly.
498	• Do not keep medicine that is out of date or that you no longer need. Be sure that if you
499	throw any medicine away, it is out of the reach of children.
500	Keep TYKERB and all medicines out of the reach of children.
501	
502	General information about TYKERB
503	Medicines are sometimes prescribed for conditions that are not mentioned in patient information
504	leaflets. Do not use TYKERB for any other condition for which it was not prescribed. Do not
505	give TYKERB to other people, even if they have the same condition that you have. It may harm
506	them.
507	
508	This leaflet summarizes the most important information about TYKERB. If you would like more
509	information, talk with your doctor. You can ask your doctor or pharmacist for information about
510	TYKERB that is written for health professionals. For more information you can call toll-free 1-
511	888-825-5249.
512	
513	What are the ingredients in TYKERB?
514	Active Ingredient: Lapatinib.
515	Inactive Ingredients: Tablet Core: Magnesium stearate, microcrystalline cellulose, povidone,
516	sodium starch glycolate. Coating: Orange film-coat: FD&C yellow #6/sunset yellow FCF
517	aluminum lake, hypromellose, macrogol/PEG 400, polysorbate 80, titanium dioxide.
518	
519	TYKERB tablets are oval, biconvex, orange, film-coated with GS XJG printed on one side.
520	



- 522523 TYKERB is a registered trademark of GlaxoSmithKline.
- 524

521

gsk GlaxoSmithKline

- 525 526 GlaxoSmithKline
- 527 Research Triangle Park, NC 27709
- 528
- 529 ©YEAR, GlaxoSmithKline. All rights reserved.
- 530
- 531 Revised: Month YEAR
- 532 TKB:XPIL
- 533